

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT COOPERATION BETWEEN SHENYANG SUNSHINE AND SUNSHINE LAKE PHARMA IN RESPECT OF CLIFUTINIB BESYLATE

This announcement is made by 3SBio Inc. (the “**Company**”) on a voluntary basis.

Shenyang Sunshine Pharmaceutical Co., Ltd. (“**Shenyang Sunshine**”), a subsidiary of the Company, entered into the cooperation agreement (the “**Agreement**”) with Sunshine Lake Pharma Co., Ltd.* (廣東東陽光藥業股份有限公司) (“**Sunshine Lake Pharma**”) and its subsidiary YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (宜昌東陽光長江藥業股份有限公司) in respect of clifutinib besylate (the “**Clifutinib**”). Pursuant to the Agreement, Shenyang Sunshine will obtain the exclusive commercialization rights of the Clifutinib, a product of Sunshine Lake Pharma, for specific indications in Mainland China. Shenyang Sunshine will pay Sunshine Lake Pharma an initial payment as well as the corresponding research and development and sales milestone payments in accordance with the Agreement. Sunshine Lake Pharma will continue to be responsible for the research and development, registration, production and other works of the Clifutinib.

There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shanghai, the PRC
25 November 2024

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Ms. ZHANG Jiao as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.